Trial intelligence / Profile preview

Ozurdex for CME and DME after cataract surgery

NCT01284478Phase 2Completed

Sponsor
Northern California Retina Vitreous Associates
Start
Jan 2011
Primary completion
Oct 2012
Modality
Implantable Devices, Implantable Hydrogels, Small Molecules
Countries
1
01

Overview

A Phase 2 trial of ozurdex in pseudophakic cystoid macular edema (PCME), diabetic macular edema (DME), sponsored by Northern California Retina Vitreous Associates. Started Jan 2011; status: completed.

02

Drugs

ozurdex
03

Conditions

pseudophakic cystoid macular edema (PCME)diabetic macular edema (DME)

Beyond the preview

Go deeper on NCT01284478.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01284478.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call